Aranesp Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects
Condition:   MDSInterventions:   Drug: Darbepoetin alfa;   Drug: PlaceboSponsor:   AmgenActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2011 Category: Research Source Type: clinical trials

Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects
Condition:   MDSInterventions:   Drug: Darbepoetin alfa;   Drug: PlaceboSponsor:   AmgenActive, not recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2011 Category: Research Source Type: clinical trials

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition:   AnemiaInterventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor:   Hoffmann-La RocheActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition:   AnemiaInterventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor:   Hoffmann-La RocheActive, not recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition:   AnemiaInterventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)Sponsors:   Hoffmann-La Roche;   Hoffmann-La RocheActive, not recruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials